ReviewAlzheimer's research & therapy2026
AI-enabled digital phenotyping for Alzheimer's disease: a review of multimodal sensor integration and symptom trajectories.
Review in Alzheimer's research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Alzheimer’s disease (AD) is characterized by progressive cognitive impairment accompanied by behavioral disturbances and neuropsychiatric manifestations. Conventional clinic-based assessments and biomarkers provide essential diagnostic information, but these episodic measurements are limited in capturing longitudinal AD-related symptoms. Digital phenotyping has emerged as a complementary approach that addresses this limitation by enabling continuous monitoring of cognitive and functional changes in everyday life. This narrative review defines digital phenotyping as a longitudinal monitoring approach that complements episodic clinical evaluations rather than replacing diagnostic assessment. Building on this, we propose a novel, stage-specific digital phenotyping framework that integrates passive and active data streams with artificial intelligence (AI) and non-AI-driven analytics to generate personalized AD symptom profiles aligned with disease progression. AI enhances the interpretability of subtle cognitive and behavioral changes observed in daily life by transforming continuously collected real-world data into clinically actionable insights across different stages of disease progression. In addition, we address three strategic priorities for advancing AI-driven digital phenotyping in AD: the development of standardized phenotyping protocols, the implementation of ambient sensing systems for later disease stages, and AI-enabled longitudinal multimodal data fusion. Moreover, we describe how increased variability and subtle disruptions in daily routines may reflect early AD progression and outline key considerations for real-world implementation, including data integration, interpretability, and clinical workflow alignment. Collectively, this review provides new insights into digital phenotyping as a scalable monitoring infrastructure that complements biomarker frameworks and enables continuous assessment across the AD continuum.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.